Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03531502 · ClinicalTrials.gov registry record · NA
Initial Management of Patients Receiving a Single Shock (IMPRESS)
A NA study, sponsored by Saint Luke's Health System.
- Terminated
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03531502: Clinical Trial NA study, sponsored by Saint Luke's Health System.
NCT03531502 is a NA study that was terminated before completion, run by Saint Luke's Health System. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03531502, a NA study, was terminated before completion, sponsored by Saint Luke's Health System.
- TERMINATED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this study is to determine the optimal treatment for patients who receive a single shock from their implantable cardioverter defibrillator (ICD). All participants in this study will be fitted with a special electrode vest to detect the origin of heart rhythm abnormalities and then they will undergo a procedure called Non-Invasive Programmed Stimulation (NIPS). This procedure involves sedating a participants with anesthesia and then using the participant's own ICD to try to stimulate the heart to go into ventricular tachycardia. If this procedure is unable to induce the participant into ventricular tachycardia, then the participant will just be managed with usual care and will not be placed on any additional medications and will not undergo an ablation. However, if the NIPS induces the ventricular tachycardia, the electrode vest will be used to determine the origin of the abnormal heart rhythm inside the heart. After a successful NIPS procedure, the participants will be randomly assigned to either be placed on medication therapy or undergo catheter ablation. The outcomes from all three groups will be compared and the researchers hope to better understand which participants are most likely to benefit from watchful waiting versus medication versus catheter ablation.
Primary Outcome
Number of recurrent ICD shocks
Interventions
- PROCEDURE Ventricular Tachycardia Ablation
- OTHER Standard Medical Therapy
- PROCEDURE Non-Invasive Programmed Stimulation (NIPS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-04-09 |
| Est. Completion | 2023-04-04 |
| Phase | NA |
Why NCT03531502 stopped before completion
NCT03531502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Ventricular Tachycardia Ablation is the first listed.
NCT03531502 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03531502 about?
NCT03531502 is a clinical study titled "Initial Management of Patients Receiving a Single Shock (IMPRESS)". The goal of this study is to determine the optimal treatment for patients who receive a single shock from their implantable cardioverter defibrillator (ICD). All participants in this study will be fitted with a special electrode vest to detect the origin of heart rhythm abnormalities and then they w...
What is the current status of trial NCT03531502?
This trial is currently terminated. It is a NA study. The enrollment target is 30 participants. The study started on 2018-04-09. Estimated completion is 2023-04-04.
What interventions are being tested in trial NCT03531502?
The interventions under investigation include: Ventricular Tachycardia Ablation (PROCEDURE), Standard Medical Therapy (OTHER), Non-Invasive Programmed Stimulation (NIPS) (PROCEDURE).
Who is sponsoring clinical trial NCT03531502?
This trial is sponsored by Saint Luke's Health System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03531502's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI